Vitamin D supplementation and sarcopenia

Completed

• Conditions: Sarcopenia and Vitamin D Deficiency; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN16665940
• Lead Sponsor: niversite d’Auvergne

Brief Summary

2018 results in https://www.ncbi.nlm.nih.gov/pubmed/30569340

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2015-12-04
• Study Start: 2018-02-20
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 115

Inclusion Criteria

1. Sarcopenic
2. Deficient in vitamin D
3. No medical history of type-2 diabetes
4. Age range of participants: 71-77

Exclusion Criteria

1. Sarcopenic subjects
2. Incidence of balance problems due to neurological disorders
3. Renal failure
4. Congestive heart failure and acute heart insufficiency as well as uncontrolled arterial hypertension or hypotension
5. Use of sedative (that could affect balance)
6. Use of vitamin D supplementation
7. Primary hyperparathyroidism

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Handgrip strength is measured using the Martin vigorimeter (Martin; Elmed, Addison, IL, USA), at baseline and 6 months.<br> 2. Appendicular skeletal muscle mass is measured using bioimpedance analysis measurements (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) at baseline and 6 months.<br> 3. 25 (OH)D levels are measured using radioimmunoassay (DiaSorin, Stillwater, MN) at baseline and 6 months<br>

Secondary Outcome Measures

Name	Time	Method
<br> 1. Weight is measured using the body composition analyzer (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) at baseline and 6 months<br> 2. BMI is calculated using the standard formula (body weight in kilograms divided by square of body height in meters). at baseline and 6 months<br> 3. Waist circumference is measured at the iliac crest at baseline and 6 months<br> 4. Fat Mass is measured using the body composition analyzer (Tanita BC-418 Segmental Body Composition Analyzer, Illinois, USA) at baseline and 6 months<br> 5. PTH is measured using a two-site immunoradiometric assay with an NH2-terminal monoclonal antibody as capture (Fitzgerald Industries International Inc., USA), at baseline and 6 months<br> 6. Serum creatinine is measured using the Jaffe kineticalkaline picrate reaction (Interpretation and Techniques, Lea and Febiger, Philadelphia), at baseline and 6 months<br>